These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Dahl-Puustinen ML; Lidén A; Alm C; Nordin C; Bertilsson L Clin Pharmacol Ther; 1989 Jul; 46(1):78-81. PubMed ID: 2743709 [TBL] [Abstract][Full Text] [Related]
4. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Spina E; Steiner E; Ericsson O; Sjöqvist F Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019 [TBL] [Abstract][Full Text] [Related]
5. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Alván G; Grind M; Graffner C; Sjöqvist F Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737 [TBL] [Abstract][Full Text] [Related]
6. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208 [TBL] [Abstract][Full Text] [Related]
7. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism. Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341 [TBL] [Abstract][Full Text] [Related]
8. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788 [TBL] [Abstract][Full Text] [Related]
9. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523 [TBL] [Abstract][Full Text] [Related]
11. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181 [TBL] [Abstract][Full Text] [Related]
12. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689 [TBL] [Abstract][Full Text] [Related]
15. Polymorphic 2-hydroxylation of desipramine. A population and family study. Dahl ML; Iselius L; Alm C; Svensson JO; Lee D; Johansson I; Ingelman-Sundberg M; Sjöqvist F Eur J Clin Pharmacol; 1993; 44(5):445-50. PubMed ID: 8359181 [TBL] [Abstract][Full Text] [Related]
16. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population. Du YL; Lou YQ Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020 [TBL] [Abstract][Full Text] [Related]
17. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Sanz EJ; Villén T; Alm C; Bertilsson L Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104 [TBL] [Abstract][Full Text] [Related]
18. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. Woolhouse NM; Adjepon-Yamoah KK; Mellström B; Hedman A; Bertilsson L; Sjöqvist F Clin Pharmacol Ther; 1984 Sep; 36(3):374-8. PubMed ID: 6467797 [TBL] [Abstract][Full Text] [Related]
19. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292 [TBL] [Abstract][Full Text] [Related]
20. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]